intradermal trivalent inactivated influenza vaccine

This refers to a trivalent inactivated influenza vaccine (TIV) administered via the intradermal route, specifically as evaluated in clinical research by the Centers for Disease Control and Prevention (CDC). In a Phase 4 trial (NCT01538940) conducted in Bangkok, Thailand, the CDC compared the immunogenicity and safety of a 15 µg dose of intradermal TIV against the standard intramuscular route in HIV-infected men who have sex with men. The vaccine contains inactivated split virions from three influenza strains (typically two Influenza A subtypes and one Influenza B lineage) to stimulate an immune response against seasonal flu. The study aimed to determine if the high density of antigen-presenting cells in the dermis would enhance the immune response in immunocompromised populations, though results indicated safety but not superior immunogenicity compared to intramuscular delivery.

Other names

intradermal influenza vaccineID-TIVintradermal TIVintradermal vaccine-Centers for Disease Control and Prevention-influenza